Rationale and design for a phase IIIb trial of first-line tremelimumab plus durvalumab versus pembrolizumab, in combination with chemotherapy, in patients with non-squamous metastatic non-small-cell lung cancer and mutations or co-mutations in <i>STK11, KEAP1</i>, or <i>KRAS</i>: the TRITON study.

Although first-line durvalumab plus chemotherapy also significantly improved PFS compared with chemotherapy (HR 0.74; 95% CI 0.62–0.89; p = 0.0009), the difference in OS did not reach statistical significance (HR 0.86; 95% CI 0.72–1.02; p = 0.0758). 34 A prespecified updated analysis of OS after a median follow-up of over 5 years 35 confirmed that adding tremelimumab to durvalumab and chemotherapy provided a sustained improvement in OS compared with chemotherapy alone (HR 0.76; 95% CI 0.64–0.89); the 5-year OS rate with tremelimumab plus durvalumab and chemotherapy (15.7%) was more than twice that with chemotherapy (6.8%).

also in 111,027 other papers